Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mF1v2jAUhu/5FVHuSYAOSqdAtbF2Q2o1RkGbdoNMcgCzYKfHNh/79XMIaHRy1NXgy9jO62Of14+PHN1uV6m3BhSUs45fD2q+ByzmCWXzjj8e3Vfb/m23Ei3JmpwMuw5qQb3he3FKhOj4eW8wBcJE8OPx4RPo/wH9bsWL+HQJsXwxTkmaBl+IWDySLB/jRWtOE28FcsGTjp8puW/1IiFRR9HdcPwlMhJDFB5aTnuXk3en7VGYi/2HqhKAD4TNjaLArDRjhQhM9oiEOcddSbxXVtpUDEFwhTEMiFwMkK9pAolxihlJBVhNMtskT4DrFGQ+iVE8XMYrYSVOlmQ7hOe+OegPurcnt7Jaq9avm+3WVbNdb9xc2SUXT7bKnAW9iDCetFut65tGCCwksXblznLbqBhwlCR1lBUqei+N5WgehOdXs59QkaVkFyxFZrtVBInuBtTH391C8hWMUAMp1Xv2jz5TaRq+MerxAReOIs5p1OOKyRJq3A9tN6LHmYRteUbtQCe3By9SEJeT/c2ZGfIDNU1pbIs0DR0FQo6H/XKiXRIGH4mAMbqjwXfKEr4Rl6fMaVYdRZ/tQWkUzTCpTxo37Va92bQ+RD+1hUpumDuFPINQ84eKc7DSZzN+LlC0K81SR09ezI77OofHJIWSSqdqyRbtw2Nh5szp7k5R0WEU/Xw3srXHNwW4e9p/GqVp0jkm1o67LmCuvVga99udXRxwJyWwQjM4FlJm4n0YbjabYEFEVRC9S8EMLw72k7vUXQHu5MIuCpgCjo5Cnxa33tsyZHvQXrvSzy1TD/8fymHjHBIVnJGLgsnOyNm/uzyM/9aozsIevKCHu2n29SSRlDNXdY6aGhXPwr9OK7tHzYevsxkteQ8ptWUUFm8x3UoU5u8w3cofkJLlkA==
2xSsH1UczW4BHm9w
Listen
